B90.8 Sequelae of tuberculosis of other organs

Name of the Condition

• Sequelae of tuberculosis of other organs

Summary

Sequelae of tuberculosis of other organs refers to the residual effects or complications that persist after the active phase of tuberculosis (TB) infection involving non-lung or non-central nervous system organs has resolved. These sequelae can include structural damage, functional impairment, or chronic symptoms resulting from prior organ involvement. The condition encompasses long-term consequences such as scarring, fibrosis, or persistent symptoms due to tissue damage during the active disease phase.

Causes

Sequelae of tuberculosis of other organs arise from the damage caused by the initial Mycobacterium tuberculosis infection in organs outside the lungs or central nervous system. During the active phase, the bacteria can destroy tissue in affected organs, leading to scarring, fibrosis, or structural changes. Even after the infection is cured, these changes may persist, resulting in chronic symptoms or functional limitations. The specific sequelae depend on the extent and location of organ involvement during the active infection.

Risk Factors

• History of active tuberculosis infection involving other organs, particularly if treatment was delayed or incomplete.
• Severe or disseminated TB during the active phase, which increases the risk of extensive tissue damage.
• Involvement of critical organs (e.g., liver, bones, lymph nodes) during the initial infection.
• Underlying conditions that may have contributed to severe disease progression.

Symptoms

Symptoms vary based on the affected organ and the extent of residual damage. Common manifestations include chronic pain, reduced organ function, scarring, or persistent inflammation. For example, bone involvement may lead to deformity or limited mobility, while lymph node sequelae may cause persistent swelling or drainage.

Diagnosis

Diagnosis involves reviewing the patient’s history of prior TB infection and current symptoms. Imaging (e.g., X-rays, CT scans) or functional tests may identify residual structural changes or organ impairment. Laboratory tests can rule out active infection, confirming the condition as a sequela rather than recurrent TB.

Treatment Options

Treatment focuses on managing symptoms and addressing functional impairment. This may include physical therapy for mobility issues, medications to reduce inflammation, or surgical interventions to correct structural damage. Management is tailored to the specific organ affected and the severity of sequelae.

Prognosis and Follow-Up

Prognosis depends on the organ involved and the extent of residual damage. Early intervention and adherence to prior TB treatment improve outcomes. Regular follow-up is essential to monitor for complications or functional decline, with adjustments to care plans as needed.

Complications

Complications may include chronic organ dysfunction, persistent pain, or increased susceptibility to secondary infections. Severe cases can lead to permanent disability or reduced quality of life, particularly if critical organs were involved during the active infection.

Lifestyle & Prevention

Lifestyle modifications, such as avoiding smoking or maintaining a healthy diet, may support organ function. Prevention focuses on ensuring complete treatment of active TB to minimize tissue damage. Vaccination (e.g., BCG) and infection control measures reduce the risk of initial TB exposure.

When to Seek Professional Help

Seek medical attention if symptoms worsen, new symptoms develop, or there are signs of active infection (e.g., fever, weight loss). Prompt evaluation is necessary to rule out recurrence or new complications.

Tips for Medical Coders

Code B90.8 is used for sequelae of tuberculosis affecting organs other than the lungs or central nervous system. Documentation should specify the affected organ(s) and confirm the condition as a residual effect of prior TB infection. Ensure the code aligns with the patient’s history and clinical findings to support accurate coding.